Details for Patent: 10,478,574
✉ Email this page to a colleague
Which drugs does patent 10,478,574 protect, and when does it expire?
Patent 10,478,574 protects ONZETRA XSAIL and XHANCE and is included in two NDAs.
This patent has five patent family members in four countries.
Summary for Patent: 10,478,574
| Title: | Nasal administration |
| Abstract: | A delivery device for and method of providing for delivery of substance to the central nervous system (CNS) of a subject, the delivery device comprising: a nosepiece unit (17) for insertion into a nasal airway (1) of a subject and comprising an outlet unit (21) which includes a nozzle (25) for delivering substance into the nasal airway of the subject; and a substance supply unit which is operable to deliver a dose of substance to the nozzle: wherein the delivery device is configured such that at least 30% of the dose as initially deposited in the nasal airway is deposited in an upper posterior region of the nasal airway, thereby providing a CNS concentration of the substance, and hence CNS effect, which is significantly greater than that which would be predicted from a counterpart blood plasma concentration of the substance. |
| Inventor(s): | Djupesland; Per Gisle (Oslo, NO), Hafner; Roderick Peter (Wiltshire, GB) |
| Assignee: | OptiNose AS (Oslo, NO) |
| Application Number: | 12/161,466 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Delivery; Device; |
Drugs Protected by US Patent 10,478,574
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Currax | ONZETRA XSAIL | sumatriptan succinate | POWDER;NASAL | 206099-001 | Jan 27, 2016 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | METHOD OF DELIVERING SUMATRIPTAN TO A NASAL CAVITY | ⤷ Try a Trial | ||||
| Optinose Us Inc | XHANCE | fluticasone propionate | SPRAY, METERED;NASAL | 209022-001 | Sep 18, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | METHOD OF DELIVERING FLUTICASONE PROPIONATE TO A NASAL AIRWAY | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 10,478,574
| PCT Information | |||
| PCT Filed | January 19, 2006 | PCT Application Number: | PCT/GB2006/000182 |
| PCT Publication Date: | July 26, 2007 | PCT Publication Number: | WO2007/083073 |
International Family Members for US Patent 10,478,574
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2006335994 | ⤷ Try a Trial | |||
| Canada | 2642608 | ⤷ Try a Trial | |||
| European Patent Office | 1984049 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
